Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Dihexa iconDihexaSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Dihexa

CognitiveResearch
~12.7 days half-life·Injection/Oral·6w on / 6w off

Also known as: PNB-0408

Two foundational mechanism papers retracted in April 2025 for data fabrication. That's the starting point for any honest conversation about Dihexa (PNB-0408), a peptidomimetic derived from angiotensin IV that activates the HGF/c-Met signaling pathway. In rodent models, it promoted synaptogenesis at picomolar concentrations. No human clinical trial has ever been conducted. The clinical prodrug fosgonimeton failed Phase 2/3 against Alzheimer's disease in 2024, missing every endpoint. Community interest persists, mostly among experimental nootropic users willing to accept preclinical-only evidence, an uncharacterized oncogenic risk, and documented purity problems across commercial sources.

What Is Dihexa?

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, also called PNB-0408, CAS 1401708-83-5) is a small peptidomimetic analog of angiotensin IV that amplifies hepatocyte growth factor signaling. Two of the papers that built its case were retracted in April 2025 for confirmed data fabrication, and Athira Pharmaceuticals settled a False Claims Act case for $4 million in January 2025. Developed at Washington State University, it binds hepatocyte growth factor with high affinity (Kd approximately 65 pM) and amplifies c-Met receptor phosphorylation. In rats, this triggered downstream PI3K/AKT signaling, driving dendritic spine formation and new synapse creation in hippocampal neurons (McCoy et al.)[1]. It reversed scopolamine-induced cognitive deficits in aged animals.

Every piece of efficacy evidence is preclinical. The clinical prodrug fosgonimeton failed Phase 2/3 LIFT-AD (n=312, September 2024) on all primary and secondary endpoints. A 2024 Huntington's disease model study (Wells et al.)[2] found no protective benefit. One independent 2025 study (Martino et al., DOI 10.1177/2689688X251392851) showed dose-dependent rescue of working memory deficits after repeated mild TBI in rodents. That result hasn't been replicated yet.

Community use continues at 5 to 20 mg daily oral. The 12.7-day half-life creates substantial plasma accumulation during a 6-week cycle. Independent testing found 9 of 12 commercial samples below 95% purity. The HGF/c-Met pathway is a well-characterized oncogenic driver; no carcinogenicity study has been conducted with Dihexa in any species.

How Dihexa Works

Dihexa binds directly to hepatocyte growth factor with a binding affinity of approximately 65 pM. When subthreshold HGF concentrations are present, it allosterically amplifies c-Met receptor phosphorylation. This triggers the PI3K/AKT cascade downstream. In hippocampal neurons, sustained PI3K/AKT signaling drives dendritic spine formation and synaptogenesis over days to weeks.

The compound also suppresses pro-inflammatory cytokines IL-1B and TNF-a while raising anti-inflammatory IL-10 (Sun et al.,; APP/PS1 Alzheimer's mouse model)[3]. That anti-neuroinflammatory effect is separate from the synaptogenic mechanism.

Unlike its parent molecule angiotensin IV, Dihexa resists enzymatic degradation. McCoy et al. [1] measured a half-life of 12.68 days IV in rats. That metabolic stability gives it oral bioavailability, confirmed in rats at 1.25 to 2.0 mg/kg gavage. No human pharmacokinetic data exists for any route.

The c-Met receptor is the same target amplified in gastric, lung, hepatic, and renal cancers. Dihexa's mechanism of action is, by definition, activation of a proto-oncogenic pathway. No long-term toxicology study has characterized this risk.

Dihexa Benefits

  • Dihexa benefits center on preclinical neurotrophic activity and HGF/c-Met pathway activation; all evidence comes from rodent models or anecdotal community reports.
  • Reversed scopolamine-induced cognitive deficits and improved spatial memory in aged rats at picomolar concentrations (McCoy et al.)[1].
  • Promoted dendritic spine formation and synaptogenesis in hippocampal neurons through PI3K/AKT signaling, a structural change distinct from acute neurotransmitter modulation.
  • Orally active and blood-brain barrier permeable in rodents. Confirmed effective at 2.0 mg/kg oral gavage; no injection required for animal efficacy.
  • Reduced neuroinflammation markers (IL-1B, TNF-a) while raising IL-10 in APP/PS1 Alzheimer's mouse models (Sun et al.)[3].
  • Dose-dependent rescue of working memory after repeated mild TBI in an independent 2025 rodent study (Martino et al., DOI 10.1177/2689688X251392851).
  • Community users report improved verbal fluency, learning speed, and working memory within weeks 2 to 4 of a 6-week oral cycle, though no validated human biomarker exists to confirm these effects.

Dihexa: Science vs Community Consensus

Divergent
Scientific Evidence
Weak
Based on 5 key studies·Research only

Severely weakened in 2024–2025.

Dosing studied: No human data established. Animal precedents: 0.5 mg/kg IP or 2.0 mg/kg oral (rat). Human equivalent dose extrapolation (~35–140 mg/day for 70 kg human) is not validated and should not be used clinically.
Read the evidence (key study, limitations)

Two primary mechanistic papers retracted April 2025 (data fabrication confirmed). Clinical prodrug fosgonimeton failed Phase 2/3 LIFT-AD on all endpoints (Sep 2024). New 2024 study shows no effect in HD rat model. New 2025 TBI study (independent lab) provides partial mechanistic rehabilitation, but not yet replicated. All efficacy evidence remains preclinical.

Key Study

Martino et al. 2025 (Neurotrauma Reports, SAGE; DOI 10.1177/2689688X251392851): Dihexa dose-dependently rescued working memory deficits after repeated mild TBI in rodents; mechanism confirmed HGF/MET-dependent via Hinge antagonist block. Best available independent post-retraction evidence.

Limitations

All efficacy data preclinical (rodent). Two founding mechanism papers retracted April 2025: data fabrication by WSU-affiliated researchers (Kawas, Harding); Athira settled False Claims Act (NIH grants) for $4M Jan 2025. Fosgonimeton (HGF/MET prodrug) failed all primary/secondary endpoints in Phase 2/3 AD trial (n=312). New 2024 HD model study (Wells, PMID 38489193) found no protective benefit. No human PK, dose-finding, safety, or efficacy studies exist.

Community Experience
Weak
3.5/5
Based on ~200–400 Reddit threads (r/nootropics, r/peptides)

Moderate cautious interest persists despite scientific setbacks.

Community dosing: 5–20 mg/day oral (most commonly reported); 1–10 mg/day subcutaneous. Anecdotal outliers up to 45 mg oral (no safety basis). Community starting dose: 5 mg/day.
Read the reports (what users report 4, common issues 5)

Community largely distinguishes "raw Dihexa" from fosgonimeton and dismisses the clinical failure as unrelated. More sophisticated users are skeptical post-retraction; broader demand appears stable.

What users report (4)
  • Improved verbal fluency and learning speed reported anecdotally
  • Perceived long-lasting effects attributed to 12+ day half-life (one cycle = weeks of activity)
  • Unique mechanism vs. racetams: HGF pathway perceived as more fundamental than cholinergic/dopaminergic
  • Oral bioavailability confirmed in animal studies: convenient vs. injection-only nootropics
Common issues (5)
  • Anxiety and irritability, especially at doses >10 mg/day: most common complaint
  • Extreme half-life makes accumulation difficult to manage; cannot stop quickly if adverse effects emerge
  • Sourcing purity: independent analysis found 9 of 12 commercial samples below 95% active compound
  • No validated biomarker to confirm cognitive effects: placebo effect cannot be excluded
  • Community mostly unaware of or dismisses April 2025 paper retractions and Athira $4M fraud settlement
Science & Community Diverge

Community use continues on the basis of older animal data and anecdotal reports. Scientific foundation has been materially undermined: two foundational mechanistic papers retracted (data fabrication), clinical prodrug failed in humans, and a 2024 rodent model found no benefit. The one new positive study (Martino 2025, TBI model, independent lab) has not changed community protocols. Community incorrectly treats fosgonimeton failure as separate from Dihexa mechanism validity.

Dihexa Dosage Guide

SpeculativePreclinical data only: no human dosing data established
LevelDose / InjectionFrequency
Beginner5 mg
DailyTrack
Moderate10 mg
DailyTrack
Aggressive20 mg
DailyTrack
Note:

Dihexa is dosed in milligrams, not micrograms. That trips people up. A 5 mg dose is 5,000 mcg, which is 10 to 100 times higher than most peptide doses. Verify your units before reconstituting or weighing.

For subcutaneous use: reconstitute a 10 mg vial with 2 mL bacteriostatic water. That gives you 5 mg/mL. A 5 mg dose is 1.0 mL, which is 100 units on a U-100 insulin syringe. A 10 mg dose uses the full vial (2.0 mL, 200 units). Let the powder dissolve without agitation.

Oral is the more common route. Take on an empty stomach. If you're measuring raw powder, you'll want a milligram-accurate scale (plus or minus 0.5 mg). Capsule products with a third-party COA are easier than self-weighing.

The 12.7-day half-life means this compound stacks in your system. By week 4, plasma levels reflect 4 to 5 half-lives of accumulation. Start low, give it time.

Independent testing found 9 of 12 commercial samples below 95% purity. Only a batch-specific HPLC plus mass spec COA from an independent third-party lab, not an in-house one, confirms purity.

Cycling Protocol

On Period
6 weeks
Off Period
6 weeks

Cycling recommended to prevent receptor desensitization. Due to lack of human safety data, longer cycles are not advised. Monitor for mood changes and discontinue if side effects emerge.

Calculate your Dihexa dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Dihexa Protocols by Goal

beginnerCommunity6 weeks on, 6 weeks off (minimum off-cycle; drug clears over ~14–18 weeks post-last-dose)
Titration
Wk 1–2
5 mg · Once daily · Oral (capsule or dissolved powder)
Standard dose
Wk 3–6
10 mg · Once daily · Oral

Expected: Anecdotal: improved verbal fluency, learning speed, and working memory by weeks 2–4. No validated human endpoint exists: self-report only.

Monitor: Weekly mood/anxiety self-check. Revert to 5 mg if irritability develops at 10 mg. LFTs and CBC at baseline and cycle end. 12.7-day half-life means steady-state accumulation is substantial by week 4: dose lower than steady-state concentration suggests.

How to Use Dihexa

  1. 1
    Step 1

    Weigh 5 mg of Dihexa powder using a milligram-accurate digital scale (plus or minus 0.5 mg). Pre-made capsules with a third-party COA are preferable to self-weighing.

  2. 2
    Take on an empty stomach once daily, morning preferred

    Swallow with water.

  3. 3
    Maintain 5 mg daily for weeks 1 to 2 (titration)

    Monitor for anxiety, irritability, or insomnia.

  4. 4
    If tolerated, increase to 10 mg daily for weeks 3 to 6

    Do not exceed 20 mg daily. Do not exceed 6 weeks per cycle.

  5. 5
    Begin 6-week off-cycle minimum

    Drug clears over approximately 14 to 18 weeks post last dose.

  6. 6
    Reconstitute a 10 mg vial with 2.0 mL bacteriostatic water

    Allow powder to dissolve without shaking. This gives 5 mg/mL concentration.

  7. 7
    Step 2

    For a 5 mg dose, draw 1.0 mL (100 units on a U-100 insulin syringe). For 10 mg, draw 2.0 mL (200 units, full vial). Use a 29 to 31 gauge needle.

  8. 8
    Inject into abdominal subcutaneous fat once daily, morning

    Rotate injection sites.

  9. 9
    Week 1: 5 mg daily

    Weeks 2 to 6: 10 mg daily or every other day if accumulation concerns arise.

  10. 10
    Store reconstituted solution at 2 to 8 degrees C

    Use within 4 weeks.

Oral Route

Subcutaneous Route

Alternative Routes

Oral (capsule or dissolved powder)

Community convention: oral dose approximately 2× SC dose, though no human bioavailability data supports this. Animal evidence: 2.0 mg/kg oral effective in rats (McCoy 2013); 0.5 mg/kg IP also effective: rough 4:1 oral:IP ratio in animals.

Most common route. Take on empty stomach for more consistent absorption. Requires mg-accurate scale (~±0.5 mg) if measuring raw powder: digital milligram scales ($15–30) are adequate. Capsule products with a COA are preferable to self-weighing.

Subcutaneous injection

Community uses 1–10 mg/day SC vs. 5–20 mg/day oral. The lower SC dose likely reflects assumption of higher bioavailability, not published guidance.

Reconstitute with bacteriostatic water (2 mL per 10 mg vial = 5 mg/mL). Inject into abdominal subcutaneous fat; rotate sites to prevent lipodystrophy. No animal data comparing SC vs. oral pharmacodynamics for Dihexa specifically.

Mixing your own vial? Use the Dihexa reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Dihexa Stacking Protocols

Works With

Avoid

c-Met inhibitors (crizotinib, cabozantinib, tepotinib, capmatinib)

Direct pharmacological antagonism: Dihexa activates c-Met; these tyrosine kinase inhibitors block it. Combining creates opposing effects and unpredictable pharmacology. More critically: anyone on c-Met inhibitors has cancer; Dihexa is absolutely contraindicated in that context.

Do not combine
Other HGF/c-Met pathway activators or pro-angiogenic growth factors

Additive activation of the HGF/c-Met proto-oncogenic pathway elevates theoretical tumor-promotion and angiogenesis risk. No combination safety data exists in any species.

Do not combine
ACE inhibitors and ARBs (e.g., lisinopril, losartan)

Pharmacological overlap via the renin-angiotensin system. Dihexa is an angiotensin IV analog. Interaction magnitude and clinical significance are unknown. No published case reports or studies; classified as precautionary.

Estimated Cost

Generic / Research
Research-grade 10 mg lyophilized vial: $50–$105 USD in the US as of Apr 2026. Examples: ~$50–$105/10 mg injectable (the upper end includes BAC water + syringes); oral capsules 10 mg × 30 count ≈ $80. Pricing below $50/10 mg is a quality flag per independent purity testing.

Pricing updated 2026-04-09

Dihexa Side Effects

The HGF/c-Met pathway is a well-characterized oncogenic driver. c-Met is amplified in gastric, lung, hepatic, and renal cancers. No carcinogenicity study has been conducted with Dihexa in any species. Anyone with a personal or family history of cancer should not use this compound. That risk is theoretical but not dismissable; it applies for the full duration of drug activity, including 14 to 18 weeks of post-cycle washout from the 12.7-day half-life.

Human safety data does not exist. Everything below comes from animal studies or anecdotal community reports across roughly 200 to 400 Reddit threads (r/nootropics, r/peptides) and ExcelMale forum discussions.

Anxiety and irritability are the most commonly reported side effects. They appear most often at doses above 10 mg daily and represent the primary reason users discontinue early. The 12.7-day half-life creates progressive plasma accumulation; by week 3, steady-state exposure is substantially higher than the nominal daily dose. Most anxiety reports resolve with dose reduction to 5 mg or switching from daily to every-other-day dosing.

Insomnia and sleep latency increases are reported alongside anxiety, particularly if the dose was escalated from the titration phase. Vivid dreams and mild headache appear during week 1 in some users.

Mood instability, including agitation and dysphoria, is reported at higher doses and during the later weeks of a 6-week cycle when accumulation is maximal.

One ExcelMale forum report (2025) described decreased hemoglobin and raised ferritin during a Dihexa cycle. Causation is unconfirmed; no controlled data exists. Liver function monitoring is warranted given that HGF is a primary hepatocyte mitogen.

Injection site reactions apply to the subcutaneous route. Rotate sites to prevent lipodystrophy. No published SC pharmacokinetic data exists for Dihexa in any species.

When to stop: new anxiety disorder symptoms, persistent insomnia lasting more than one week, mood instability, or any signs of hepatic dysfunction. Because of the half-life, drug activity persists 6 to 10 weeks after the last dose. Emerging side effects post-cycle still warrant medical evaluation.

Contraindicated in pregnancy and breastfeeding. No reproductive toxicology data exists. Contraindicated in individuals under 25, those with liver disease, and anyone with known hypersensitivity to angiotensin-derived compounds.

Common Issues & Solutions

Anxiety or irritability during cycle: reduce dose to 5 mg or switch from daily to every-other-day dosing. The 12.7-day half-life creates progressive plasma accumulation: week 3 steady-state exposure is substantially higher than the nominal daily dose suggests. Most anxiety reports resolve with dose reduction.

Cannot tell if it is working: no validated human biomarker for Dihexa's effects exists. Without objective cognitive testing at baseline and week 4 (MoCA, Stroop, dual n-back), any perceived benefit is indistinguishable from placebo. Nootropic placebo effect is strong and well-documented.

Effects persist after stopping: pharmacokinetically expected: 12.7-day half-life means ~50% of drug remains at day 13, ~25% at day 26. Full clearance takes approximately 14–18 weeks post-last-dose after a 6-week cycle. Persistent effects post-cessation are not evidence of permanent structural change.

Purity and product integrity: only a batch-specific HPLC + MS certificate of analysis from an independent third-party lab confirms what a vial holds. Independent 2026 testing found 9 of 12 commercial Dihexa samples below 95% active compound. Lower price does not equal lower risk: some cheap products are mis-labeled compounds.

Milligram vs. microgram confusion: Dihexa is dosed in milligrams (mg), not micrograms (mcg). A 5 mg dose equals 5,000 mcg: 10–100× higher than most peptide doses. Verify units before reconstituting, weighing, or dosing.

Ask AI about this page

Ask AI for a second opinion on Dihexa dosing and side effects

Contraindications

  • Any active or history of cancer: HGF/c-Met pathway activation may promote tumor growth
  • Pregnancy or breastfeeding: no reproductive toxicology data exists
  • Individuals under 25: brain development still ongoing
  • Known hypersensitivity to angiotensin-derived compounds
  • Liver disease: HGF is a hepatocyte-targeted growth factor
  • Current use of c-Met inhibitors (crizotinib, cabozantinib, tepotinib, capmatinib) indicates active cancer and direct pharmacological antagonism

Drug Interactions

  • ACE inhibitors and ARBs: potential interaction via the renin-angiotensin system
  • Anticoagulants: HGF/c-Met signaling may affect platelet function; monitor closely
  • Cancer therapeutics (c-Met inhibitors such as crizotinib, cabozantinib): direct pharmacological antagonism
  • Other nootropics or cognitive enhancers: no interaction data available; use caution with stacking

Product Quality

Recommended Monitoring

TestWhenTarget
Baseline cognitive assessmentBefore cycle start; repeat at week 4 and week 6Personal baseline; validated tools: MoCA (≥26/30 normal), Stroop test, or dual n-back app with tracked scores
Liver function tests (ALT, AST, GGT, bilirubin)Baseline before cycle start; end of cycle (week 6)ALT/AST <40 U/L; GGT <50 U/L; total bilirubin <1.2 mg/dL
CBC with differential (hemoglobin, hematocrit, ferritin)Baseline and cycle end (week 6)Hemoglobin: 13.5–17.5 g/dL (male), 12–15.5 g/dL (female); ferritin 12–300 ng/mL
Mood and anxiety self-assessmentWeekly throughout cycleAny new or worsening anxiety disorder symptoms, persistent insomnia, or mood instability → discontinue
Baseline cognitive assessment

Without an objective baseline, cognitive effects cannot be separated from placebo. Self-report without testing has no evidential value for a compound with no validated human biomarker.

Liver function tests (ALT, AST, GGT, bilirubin)

HGF is a primary hepatocyte mitogen; liver disease is a listed contraindication. Essential before initiating any HGF/c-Met pathway compound.

CBC with differential (hemoglobin, hematocrit, ferritin)

Community report of decreased hemoglobin and elevated ferritin during Dihexa use (ExcelMale forums, 2025). Causation unconfirmed; monitoring is precautionary given no human safety data.

Mood and anxiety self-assessment

Anxiety and irritability are the most commonly reported side effects and the primary reason for early discontinuation. Systematic weekly check prevents normalization of emerging dysphoria.

Dihexa Before and After

Week 1

Anecdotal reports suggest initial improvements in focus and mental clarity. No clinical data supports this timeline. Effects may be placebo.

Weeks 2-4

Animal studies show measurable synaptogenesis and improved spatial memory within this window. Anecdotal reports describe enhanced learning capacity and memory recall.

Weeks 4-6

In rat models, peak cognitive enhancement and synaptic remodeling observed by this period. Recommended cycle endpoint.

What to Expect

Week 1, Titration and accumulation onset: No human data backs any timeline for Dihexa. Rodent models required sustained HGF/c-Met activation over days to weeks before measurable synaptogenesis appeared. Plasma accumulation begins immediately, but levels are still well below projected steady state. Some community users report early focus improvements within days. That likely reflects placebo or a transient stimulant-like response at initiation; the pharmacokinetics predict effective concentrations don't peak until weeks 2 to 3. Watch for mild headache, vivid dreams, or irritability.

Weeks 2 to 4, Accumulation and potential pharmacological onset: Rat models showed measurable synaptogenesis and spatial memory improvement in this window at effective dose ranges. Dendritic spine formation requires sustained PI3K/AKT signaling over multiple days. Community reports consistently describe this as the window for verbal fluency improvement, improved learning speed, and working memory gains. Some users describe increased motivation alongside cognitive effects. Anxiety and irritability are the most common complaints here, particularly if the dose was increased from week 1. Sleep onset delays appear in some users.

Weeks 4 to 6, Peak cycle and recommended endpoint: Rodent studies showed peak cognitive enhancement and synaptic remodeling by this period. No human or long-cycle animal data exists. Six weeks is a community standard, not a clinically derived endpoint. Users report peak subjective effects. Some plateau and consider dose increases, which is not recommended given how much the drug has accumulated by this point. Begin the 6-week washout after week 6.

Weeks 7 to 18, Long washout with persistent drug activity: The 12.7-day half-life means approximately 50% of the drug remains at week 8 post last dose, 25% at week 10. Effective clearance takes 14 to 18 weeks. Any structural synaptic changes induced (if they occurred) may outlast drug clearance. Community members describe "lasting effects" 2 to 3 weeks post-cycle as evidence of structural synaptic changes. Pharmacokinetically, partial drug activity persists throughout this period. The oncogenic risk from c-Met activation, if real, applies during this extended window too.

Detailed Timeline: Science vs Community

Week 1
Science

No human data. Rodent models require sustained HGF/c-Met activation for synaptogenesis (days to weeks). Single-dose structural changes not documented. Plasma accumulation begins; levels still well below projected steady-state.

Community

Some users report early improvements in focus within days. Likely reflects placebo or transient stimulant-like response at initiation. Half-life pharmacokinetics mean effective concentrations may not peak until week 2–3.

Weeks 2–4
Science

Rat models: measurable synaptogenesis and spatial memory improvement within this window at effective dose ranges. Dendritic spine formation requires sustained PI3K/AKT signaling over multiple days.

Community

Most commonly reported window for verbal fluency improvement, enhanced learning speed, and working memory gains. Some users describe increased motivation alongside cognitive effects.

Weeks 4–6
Science

Rodent studies show peak cognitive enhancement and synaptic remodeling by this period. No human or long-cycle animal data exists. Six weeks is the community-standard cycle length, not a clinically derived endpoint.

Community

Reported peak subjective effects. Some users plateau and consider dose increase (not recommended given accumulation). Cycle end: begin 6-week washout.

Weeks 7–18 (off-cycle / washout)
Science

12.7-day half-life: ~50% drug remaining at week 8 post-last-dose, ~25% at week 10, effectively cleared by weeks 14–18. Any structural synaptic changes induced (if they occurred) may outlast drug clearance. Oncogenic risk, if any, applies during this extended window too.

Community

Community describes "lasting effects" 2–3 weeks post-cycle as evidence of structural synaptic changes. Pharmacokinetically, partial drug activity persists throughout this period: not necessarily indicative of permanent neuroplasticity.

Pharmacokinetics

Half-Life
304h
Bioavailability
Oral: demonstrated in rats (effective via gavage at 1.25-2.0 mg/kg). Human bioavailability unknown.
Tmax
Not characterized in any species
Data Confidence
low

Source: McCoy et al. 2013 (PMID 23055539): t1/2 = 12.68 days IV in rats. No human PK data.

Pharmacokinetics: Active Dose Over Time

t½ = ~12.7 days (IV, rat)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Dihexa

  • Researchers investigating HGF/c-Met pathway activation
  • Individuals exploring experimental nootropics under medical supervision
  • Adults interested in preclinical neuroprotective compounds
  • Those studying age-related cognitive decline interventions

Related Peptides

What Changed for Dihexa

  1. RegulatoryEffective

    Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.

    What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).

    Also covers: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epithalon, GHK-Cu, LL-37, PEG-MGF, Melanotan II

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Dates to watch

  1. Committee review

    FDA intends to consult its compounding advisory committee on adding these peptides to the 503A bulks list, per FDA.

    What this does not mean: No meeting date is set yet. A committee vote is advice to FDA, not a rule; the 503A bulks list changes only through notice-and-comment rulemaking.

    Also covers: LL-37, GHK-Cu, Melanotan II, PEG-MGF

Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations

References

  1. [1]Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents (McCoy et al., J Pharmacol Exp Ther, 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats (J Huntingtons Dis 2024) (opens in a new tab)(n=312,)PubMed (opens in a new tab)PubMed
  3. [3]AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway (Sun et al., Brain Sciences, 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 1 month, refrigerate for long-term storage
After Reconstitution
Refrigerate at 2-8°C, use within 4 weeks
Temperature
2-8°C (36-46°F) recommended

Frequently Asked Questions

Fosgonimeton (a pro-drug of Dihexa) failed Phase 2/3 (LIFT-AD, 2024) against mild-to-moderate Alzheimer's disease; missing all primary and secondary endpoints. This doesn't definitively disprove the HGF/c-Met mechanism, but it is a significant setback for the entire hypothesis. Disease-stage selection, dose, or the fundamental limits of preclinical-to-human translation may all be factors.

The half-life of ~12.7 days (IV rat) creates accumulation with daily dosing; plasma levels will stack substantially over a 6-week cycle. Some community members dose every other day or 3x/week to reduce accumulation. No human PK data exists to guide optimal frequency.

Theoretical but not dismissable. The HGF/c-Met pathway is a well-characterized oncogenic driver; c-Met is amplified in gastric, lung, hepatic, and renal cancers. No carcinogenicity study has been conducted with Dihexa in any species. Anyone with a personal or family history of cancer should not use this compound.

Animal studies established oral activity (2.0 mg/kg gavage was effective), and the compound's stability supports oral use. Subcutaneous is preferred in some community protocols for theoretically higher and more consistent bioavailability, though no human comparison data exists.

No validated human biomarker exists for Dihexa's cognitive effects. Anecdotal self-assessment is the only tool available. Given the strong placebo effect for nootropics and the complete absence of human trial data, you cannot distinguish real effects from expectation bias.